Lawrence Kelly, MD
Psychiatry · Charleston, WVNPI 1629031901
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,957 of the $40,766 with a category attached, or 66.1%. Teva Pharmaceuticals USA, Inc. accounts for 87.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $19,107 and has fallen 94.4% since, to $1,078 in 2025. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $78.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$36K
- AbbVie$2K
- Lundbeck LLC$548
- Otsuka America Pharmaceutical, Inc.$461
- Axsome Therapeutics, Inc.$442
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$439
- plus $1K from 21 others
What the payments were for
- Consulting fees$3,0007%
- Speaking & faculty fees$26,95766%
- Travel & lodging$1,6034%
- Food & beverage$8,96522%
- Education$2411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 214 | $35,809 |
| AbbVie(2 entities) | 124 | $1,665 |
| Lundbeck LLC | 35 | $548 |
| Otsuka America Pharmaceutical, Inc. | 19 | $461 |
| Axsome Therapeutics, Inc. | 20 | $442 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $348 |
| Johnson & Johnson | 3 | $140 |
| Eisai Inc. | 9 | $137 |
| Vanda Pharmaceuticals Inc. | 6 | $111 |
| Amgen | 5 | $99 |
| Avanir Pharmaceuticals, Inc. | 6 | $88 |
| MDD US Operations, LLC | 2 | $85 |
| Corium, LLC | 2 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $51 |
| Shire North American Group Inc | 2 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Alkermes, Inc. | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Neos Therapeutics, LP | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$31,745
- Austedo XR$108
How this compares
$40,766 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 38 | $331,482 |
| Austedo XrDeutetrabenazine | 38 | $266,374 |
| RexultiBrexpiprazole | 32 | $65,242 |
| NuplazidPimavanserin Tartrate | 11 | $55,077 |
| VraylarCariprazine Hcl | 32 | $43,999 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $31,268 |
| TrintellixVortioxetine Hydrobromide | 42 | $31,152 |
| CaplytaLumateperone Tosylate | 14 | $22,669 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $20,236 |
| ZyprexaOlanzapine | 12 | $12,887 |
| BelsomraSuvorexant | 32 | $12,800 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 190 | $6,912 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $4,688 |
| Quetiapine Fumarate | 207 | $3,964 |
| Gabapentin | 271 | $3,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $35,809 | $597,85676 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $461 | $65,24232 claims |
| AbbVieVraylar | $1,665 | $43,99932 claims |
| Axsome Therapeutics, Inc.Auvelity | $442 | $31,26813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $348 | $31,15242 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $439 | $22,66914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Charleston
- Melissa MoodyCharleston$1.2M
- Fahd MousaCharleston$200K
- Sidney LerfaldCharleston$14K
- Kiran DevarajCharleston$9K
- Krista RhodesCharleston$4K
- Veena BhanotCharleston$833
- Timothy ThistlethwaiteCharleston$773
- Nohl BraunCharleston$612
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.